Exploratory analysis from Farxiga DAPA-HF Phase III trial will provide insights on the onset of type-2 diabetes in heart failure patients
Sub-analysis from the DECLARE Phase III trial to highlight Farxiga’s effect on fast renal decline
AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts, including four oral presentations, covering trials that showcase the depth and breadth of potential cardio, renal and metabolic benefits for patients across AstraZeneca’s portfolio.
- An oral presentation of data from the DAPA-HF trial showing the effect of Farxiga (dapagliflozin) on the incidence of new onset of type-2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF) (Abstract #271-OR)1
- New sub-analysis from the DECLARE-TIMI 58 trial, presented orally, providing insights on Farxiga’s effect on fast kidney function decline in T2D patients with established or increased risk for cardiovascular disease (Abstract #303-OR)2
- An analysis of the DAPA-HF trial examining if background T2D therapy impacts the benefits of Farxiga in heart failure (HF) (Abstract #1112-P)3
- A new analysis of the global observational DISCOVER real world evidence study, presented orally, reporting health-related quality of life factors in patients with T2D initiating a 2nd-line glucose-lowering therapy (Abstract #40-OR)4
- An oral presentation of new Phase II data on investigational cotadutide, a dual receptor agonist with balanced GLP-1 and glucagon activity, showing positive effect on blood glucose levels and changes in liver fat and glycogen stores in patients with T2D (Abstract #354-OR)5
- Brilinta (ticagrelor) data on duration of T2D, baseline HbA1c levels as well as the impact of blood sugar-lowering background therapies on outcomes in T2D patients with coronary artery disease (THEMIS diabetes subgroup) (Abstract #403-P)6
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “An overwhelming majority of people with type-2 diabetes also have at least one other cardiovascular, renal or metabolic disease. The breadth and depth of data we are presenting at ADA 2020 demonstrates our commitment to developing treatment options for patients living with diabetes that go beyond glycaemic control to also protect the heart, liver and kidneys.”
In addition to its robust clinical data, AstraZeneca will also present results from a global survey of more than 1,600 physicians in 18 countries examining primary care approaches and clinical inertia in the treatment of patients with T2D.
Key abstracts and other notable abstracts to be presented at ADA:
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
1. Inzucchi SE et al. Effect of Dapagli?ozin on the Incidence Of Diabetes: A Prespeci?ed Exploratory Analysis From DAPA-HF. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
2. Raz I et al. Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analyses from the DECLARE-TIMI 58 Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
3. Docherty KF et al. Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
4. Nicolucci A et al. Quality of Life in People with Type 2 Diabetes Following Initiation of Second-Line Therapy: DISCOVER. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
5. Robertson D et al. Cotadutide (MEDI0382), a Dual Receptor Agonist With Glucagon-like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
6. Leiter La et al. Impact of Diabetes-Related Factors And Background Antihyperglycemic Therapy On The Efficacy And Safety Of Ticagrelor Added To Aspirin: Insights From The THEMIS Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
7. Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000–3.